Abstract: Psoriasis is a chronic inflammatory skin disease induced by a combination of genetics and environment and mediated by immunity. Tyrosine kinase 2 (TYK2) and Signal Transducer and Activator of Transcription (STAT) protein are the main pathways of cytokine regulation and play critical roles in mediating inflammation and immune response. Deucravacitinib is the first innovative drug recently approved by the U.S. Food and Drug Administration (FDA) as the only TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. It mediates the transcription of key inflammatory mediators through the TYK2/STAT pathway and in the pathogenesis of psoriasis. Compared with other Janus Kinase (JAK) inhibitors, deucravacitinib is more promising for its highly selective inhibition of inflammatory pathways through metabotropic inhibition. This paper summarizes the mechanism of action and research progress of deucravacitinib in the treatment of psoriasis.

Key words: deucravacitinib, TYK2 inhibitors, psoriasis, allosteric inhibition